Sacristán J A, Oliva J, Del Llano J, Prieto L, Pinto J L
Departamento de Investigación Clínica, Lilly S.A. Madrid, Spain.
Gac Sanit. 2002 Jul-Aug;16(4):334-43. doi: 10.1016/s0213-9111(02)71933-x.
Despite the growing recognition of the potential applications of cost-effectiveness assessments, a criterion to establish what is an efficient health technology does not exist in Spain. The objective of this work is to describe the limits and the criteria used in Spain to recommend the adoption of health interventions.
A review of the economic evaluations of health technologies published in Spain from 1990 to 2001 was conducted. Complete economic assessments in which the cost-effectiveness ratio was expressed as cost per life-year gained (LYG), cost per quality-adjusted-life-year (QALY) or cost per saved live were selected. Those interventions in which the authors established recommendations (adoption or rejection) and the criteria used were analyzed.
Twenty (20%) of the 100 complete economic evaluations fulfilled the selection criteria. In16 studies, the results were expressed as cost per LYG, in 6 studies as cost per QALY and in 1 as cost per saved live. A total of 82 health interventions were assessed and some kind of recommendation was established in 44 of them. All technologies with a cost-effectiveness ratio lower than 30,000 euros (5 million pesetas) per LYG were recommended for adoption by the authors. Up to that limit there was no a clear tendency.
Although the results must be interpreted with much precaution, given the limitations of the study, the limits of cost-effectiveness presented in this work could be a first reference to which would be an efficient health intervention in Spain.
尽管成本效益评估的潜在应用得到了越来越多的认可,但西班牙尚无确定何种健康技术为高效技术的标准。本研究的目的是描述西班牙在推荐采用健康干预措施时所使用的限制条件和标准。
对1990年至2001年在西班牙发表的健康技术经济评估进行综述。选取了完整的经济评估,其中成本效益比以每获得的生命年(LYG)成本、每质量调整生命年(QALY)成本或每挽救生命成本来表示。分析了作者在其中提出建议(采用或拒绝)的那些干预措施及其所使用的标准。
100项完整的经济评估中有20项(20%)符合选择标准。16项研究的结果以每LYG成本表示,6项研究以每QALY成本表示,1项研究以每挽救生命成本表示。总共评估了82项健康干预措施,其中44项提出了某种建议。作者建议采用所有成本效益比低于每LYG 30,000欧元(500万比塞塔)的技术。在该限制范围内没有明显趋势。
尽管鉴于本研究的局限性,结果必须谨慎解读,但本研究中提出的成本效益限制可能是西班牙高效健康干预措施的首个参考依据。